Other Arrhythmia 426.x, 427.0, 427.20, 427.81, 427.9, 427.1, 427.4x, 37.9x, 996.04, v53.32, 37.7x, 37.8x, 996.01, v45.00, v45.01, v45.02, v45.09, v53 .31 Stroke/Transient ischemic attack 433.x, 434.x, 435.x, 436 .00 Valvular disease 394.x-397.1, 424.x, 746.3-746.6, v42.2, v43.3 Peripheral arterial disease 38. 03, 38.04, 38.05, 38.08, 38.33-38.48, 39.22-39.29, 440.2x, 440.3x, 440.4x, 441.x, 443.x, 445.x, 447.10, 557.10, 557.90, v43.4 00, 456.0, 456.20, 530.21, 530.70, 530.82, 531.0x, 531.2x, 531.4x, 531.6x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 534.0x, 534.2x, 534.4x, 534.6x, 535.x1, 537.83, 537.84, 562.02, 562.03, 562.12, 562.13, 569.3, 569.85, 578.x Peptic ulcer disease 531.7, 531.0, 531.71, 531.9, 531.90, 531.91, 532.7, 532.70, 532.71, 532.9x, 533.7x, 534.7x, 534 296.2x, 296.3x, 296.5x, 296.82, 300.40, 301.12, 309.0, 309.10, 174.x, 175.x, 238.6, 273.3 Hypothyroidism 243, 244.x Obesity 278.0x, 649.1x, v85.3x, v85.4 Outcomes Myocardial Infarction Primary 410.xx Secondary 410.x1 Bleed Primary position 255.41, 376.32, 379.23, 423.0, 459.0, 569.69, 597.7, 719.1x, 784.7, 784.8, 785.59, 786.3, 860.2, 860.3, 860.4, 860.5, 456.00, 456.0, 456.20, 530.21, 530.70, 530.82, 531.0x, 531.2x, 531.4x, 531.6x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 534.0x, 534.2x, 534.4x, 534.6x, 535.x1, 537.83, 537.84, 562.02, 562.03, 562.12, 562.13, 569.3, 569.85, 578.x Primary or secondary 430, 431, 432, 432.0, 432.1, 432.9 Supplemental Table 2 : Baseline characteristics in the unmatched, propensity-score (PS) matched, and inverse probability of treatment weighted (IPTW) 3-month landmark drug-eluting stent cohort. Table 4 : Baseline characteristics in the unmatched, propensity-score (PS) matched, and inverse probability of treatment weighted (IPTW) 6-month landmark drug-eluting stent cohort. All values are % unless otherwise noted. Table 5 : Baseline characteristics in the unmatched, propensity-score (PS) matched, and inverse probability of treatment weighted (IPTW) 6-month landmark bare metal stent cohort. All values are % unless otherwise noted. UNMATCHED PS-MATCHED IPTW Table 6 : Baseline characteristics in the unmatched, propensity-score (PS) matched, and inverse probability of treatment weighted (IPTW) 12-month landmark drug-eluting stent cohort. All values are % unless otherwise noted. UNMATCHED PS-MATCHED IPTW Table 7 : Baseline characteristics in the unmatched, propensity-score (PS) matched, and inverse probability of treatment weighted (IPTW) 12-month landmark bare metal stent cohort. All values are % unless otherwise noted. UNMATCHED PS-MATCHED IPTW 
